Cardio Round-up: Cardiovascular Risk and Income, Drinking and AFib, and More

Interesting studies in this week’s edition looking at the links between income and cardiovascular risk, as well as the risks posed by frequent alcohol consumption!

Changes in Income Linked to Changes in Cardiovascular Risk

The links between a higher income level and better overall cardiovascular health have been documented. Researchers for this study sought to examine the impact of losing income on cardiovascular health. Drawing on the ARIC ongoing community study, the analysis included almost 9,000 individuals, about 10% of whom had experienced an income drop during the study period. The results suggested that lowering income was associated with increased cardiovascular risk. “Health professionals should have greater awareness of the influence of income change on the health of their patients,” the authors wrote.

Cardiovascular Risk Linked with Changes in Income

Drinking Frequently Heightens Risk for New-onset AFib

Links between alcohol consumption and atrial fibrillation (AFib) risk have been shown in previous research. The researchers for this paper focused on the frequency of drinking. The analysis looked at data on over nine million individuals, who had answered questionnaires about alcohol consumption and overall health. The results suggested that people who drink once per week had the lowest risk of new-onset AFib compared to those who drank every day. “Repeated episodes of atrial fibrillation triggered by alcohol may lead to overt disease,” one of the researchers said. “In addition, drinking can provoke sleep disturbance which is a known risk factor for AFib.”

Frequent Drinking Raises Risk for New AFib

Ticagrelor Reduces Post-PCI, Post-DAPT Bleeding

Researchers looking for an optimal antiplatelet regimen in patients undergoing multivessel percutaneous coronary intervention (PCI) conducted this post-hoc study of an experimental regimen of a month of dual antiplatelet therapy (DAPT) followed by 23 months of ticagrelor monotherapy compared to a reference regimen of 12 months DAPT and 12 months aspirin. The study included more than 15,000 participants who had undergone multivessel PCI and were at high risk for ischemic and bleeding events. An interaction between the ticagrelor regimen and a reduction in the composite study endpoint was reported (driven by a reduction in all-cause mortality). “These findings should be interpreted as hypothesis-generating and need to be replicated in future dedicated randomized trials,” the researchers added.

Ticagrelor Post-DAPT Reduces Bleeding after PCI